The 21st Century Cures Act, in many ways, helps drugs in other disease areas going through review with FDA get to the same standard of the oncology area, said Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN).
The 21st Century Cures Act, in many ways, helps drugs in other disease areas going through review with FDA get to the same standard of the oncology area, said Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN).
Transcript
How do you think the provisions within the 21st Century Cures Act would impact cancer care in the United States?
The 21st Century Cures Act really was about trying to ensure FDA used its maximum flexibility and was really forward leaning in terms of how they handled drug development. FDA is a large organization and drug review is done by disease type. The oncology review divisions have traditionally been very forward leaning in terms of accepting novel endpoints, novel trial designs, smaller trials, and using more of the accelerated pathways. So, in many ways, 21st Century Cures, from a messaging standpoint, was telling FDA to sort of behave in that aggressive way across disease types. So, it was really an affirmation of the way the cancer review divisions were already behaving.
But one of the things it also did was formalize the Oncology Center of Excellence, and it was really a recognition that somewhere around 40% of all drugs being developed today are for oncology indications. So, it’s the biggest workload that FDA has, and there’s a recognition that that expertise needs to be shared across different reviews. And, also, the message is that FDA is not there to just simply review applications, but they’re really there to develop and promulgate better regulatory science, to help develop the tools that makes it easier and faster to get drugs to patients.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More